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Background: Anthracyclines, such as adriamycin, are highly effective chemotherapeutic agents, but are well known to cause myocardial 
dysfunction and life-threatening heart failure by unclear mechanisms.
Methods: To generate new hypotheses about its etiology, we performed genome-wide transcript analysis with the Affymetrix U133+2 GeneChip 
on whole-blood RNA from women receiving chemotherapy with anthracyclines who either did (Group A, n=5), or did not (Group B, n=10) develop 
subsequent cardiac dysfunction, as defined by ejection fractions (EF)<40%. Women with non-ischemic cardiomyopathy not due to chemotherapy 
(Group C, n=4) were compared to breast cancer patients prior to chemo with normal EF (Group D, n=5) to identify heart failure-related transcripts 
independent of chemotherapy.
Results: Analysis of the results indicates that patients who developed heart failure after chemotherapy had 260 transcripts that differed >2-fold 
(p<0.05) compared to women receiving chemo who did not develop heart failure (A vs B). Most of these transcripts (205) were not shared by women 
who developed heart failure independent of chemotherapy (C vs D). Pathway analysis of the differentially expressed genes indicated an enrichment 
in apoptosis-related transcripts, and notably, women with chemo-induced cardiomyopathy had a 4.8-fold decrease in the oncogene T-cell leukemia/
lymphoma 1A (TCL1A). TCL1A is expressed in both cardiac and skeletal muscle, and is a known co-activator for AKT, one of the major pro-survival 
factors for cardiomyocytes. Additionally, genome-wide SNP analysis has previously identified TCL1A SNPs strongly associated with musculoskeletal 
adverse events in women receiving aromatase inhibitors (AI). The variant allele at rs11849538 is quite common (22-34% heterozygous, 6% 
homozygous), and creates an estrogen receptor binding site.
Conclusions: We propose that chemo-induced cardiomyopathy may be due to a genetic predisposition to reduced TCL1A levels, reducing AKT 
activity and thereby causing increased apoptotic sensitivity to adriamycin. If so, screening for TCL1A SNPs might identify women at greatest risk of 
chemo-induced heart failure.
